18F-FES PET/CT对接受内分泌治疗联合细胞周期蛋白依赖性激酶4/6抑制剂治疗的复发或转移性乳腺癌患者的预测和预后价值
本研究基于前瞻性队列的回顾性分析,纳入127例ER阳性、HER2阴性复发/转移性乳腺癌女性,评估治疗前18F-FES PET/CT对CDK4/6抑制剂联合内分泌治疗疗效的预测和预后价值。FES阴性组(25例)较FES阳性组(102例)的无进展生存和总生存显著更差,风险比分别为3.9(P<0.001)和3.7(P=0.008)。
要点
- 18F-FES PET/CT显示的ER表达状态与CDK4/6抑制剂联合内分泌治疗后的PFS和OS相关。
- FES阴性组(含完全阴性3例和混合22例)PFS风险比为3.9(P<0.001),OS风险比为3.7(P=0.008)。
- FES阴性组内分泌治疗获益降低在绝经状态、内分泌敏感性和治疗方案各亚组中一致。
核心结论
- 18F-FES PET/CT确定的ER表达可预测CDK4/6抑制剂为基础的内分泌治疗疗效,并对复发/转移性ER阳性、HER2阴性乳腺癌具有生存预后价值。
研究设计与样本
- 从2021年4月至2023年4月在Asan Medical Center前瞻性入组的18F-FES上市后监测队列中识别患者,进行回顾性分析。
- 纳入接受CDK4/6抑制剂为基础的内分泌治疗且治疗前接受18F-FES PET/CT的ER阳性、HER2阴性复发/转移性乳腺癌患者,共127例女性。
主要发现
- 内分泌治疗使用芳香化酶抑制剂96例(76%),氟维司群31例(24%)。
- 「伴FES阴性」组25例(20%),其中完全阴性3例、混合22例;「FES阳性」组102例(80%)。
- 「伴FES阴性」组对比「FES阳性」组:PFS风险比3.9(P<0.001),OS风险比3.7(P=0.008)。
- 「伴FES阴性」组内分泌治疗获益降低在绝经状态、内分泌敏感性和治疗方案等亚组中一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Estrogen receptor (ER) expression and heterogeneity affect endocrine therapy efficacy. 18F-fluoroestradiol (18F-FES) PET/CT is an effective non-invasive method to analyze systemic ER expression. This study aimed to examine the predictive/prognostic value of 18F-FES PET/CT for patients treated with endocrine therapy plus cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. METHODS: Patients were identified from a prospective cohort for post-marketing surveillance of 18F-FES enrolled between April 2021 and April 2023 at Asan Medical Center. In this retrospective analysis, patients with ER-positive, HER2-negative recurrent/metastatic breast cancer who underwent CDK4/6 inhibitor-based endocrine therapy and pre-treatment 18F-FES PET/CT were included. RESULTS: A total of 127 women were included. The endocrine therapy used was aromatase inhibitors in 96 patients (76%) and fulvestrant in 31 patients (24%). There were 25 (20%) and 102 (80%) patients in the "with FES-negative" (3 completely negative, 22 mixed) and "FES-positive" groups, respectively. 18F-FES status correlated with progression-free survival (PFS) following endocrine therapy with CDK4/6 inhibitors and overall survival (OS) ("with FES-negative" group: hazard ratio for PFS, 3.9, p < 0.001; for OS, 3.7, p = 0.008). Reduced benefit from endocrine treatment in the "with FES-negative" group was consistent across subgroups including menopausal status, endocrine sensitivity, and treatment regimen. CONCLUSION: ER expression determined by 18F-FES PET/CT predicted the efficacy of CDK4/6 inhibitor-based endocrine therapy and was prognostic for survival in recurrent/metastatic ER-positive, HER2-negative breast cancer.
引用
- Jeong H, Ryu J, Jeong JH, et al. Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors. Eur J Nucl Med Mol Imaging. 2025. PMID: 39806206. doi:10.1007/s00259-024-07058-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。